More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/PJ-34 [344458-15-7]
Chemical Structure
Chemical Structure
Chemical Structure

PJ-34 [344458-15-7]

Research Use Only
AG-CR1-0100
AdipoGen Life Sciences
CAS Number344458-15-7
DownloadMSDS
Product group Chemicals
Estimated Purity>98%
Molecular Weight295.2 . 36.5
Price on request
Packing Size
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    PJ-34 [344458-15-7]
  • Delivery Days Customer
    10
  • CAS Number
    344458-15-7
  • Certification
    Research Use Only
  • Estimated Purity
    >98%
  • Molecular Formula
    C17H17N3O2 . HCl
  • Molecular Weight
    295.2 . 36.5
  • Scientific Description
    Chemical. CAS: 344458-15-7. Formula: C17H17N3O2 . HCl. MW: 295.2 . 36.5. Potent, water soluble poly(ADP-ribose) polymerase (PARP) inhibitor. Inhibits peroxynitrite-induced cell necrosis. Shows significant, dose-dependent anti-inflammatory effects in a variety of local inflammation models. Provides cardioprotection by decreasing myocardial infarct size. Shows protective effects in models of stroke. Suppresses cell growth in liver cancer cells. - Potent, water soluble poly(ADP-ribose) polymerase (PARP) inhibitor. Inhibits peroxynitrite-induced cell necrosis. Shows significant, dose-dependent anti-inflammatory effects in a variety of local inflammation models. Provides cardioprotection by decreasing myocardial infarct size. Shows protective effects in models of stroke. Suppresses cell growth in liver cancer cells.
  • SMILES
    Cl.CN(C)CC(=O)NC1=CC2=C(NC(=O)C3=CC=CC=C23)C=C1
  • Storage Instruction
    2°C to 8°C
  • UNSPSC
    12352200

References

  • Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation: F. Garcia Soriano, et al.; Nat. Med. 7, 108 (2001)
  • Protective effects of PJ34, a novel, potent inhibitor of poly(ADP-ribose) polymerase (PARP) in in vitro and in vivo models of stroke: G.E. Abdelkarim, et al.; Int. J. Mol. Med. 7, 255 (2001)
  • Anti-inflammatory effects of a novel, potent inhibitor of poly (ADP-ribose) polymerase: J.G. Mabley, et al.; Inflamm. Res. 50, 561 (2001)
  • Pharmacologic inhibition of poly(adenosine diphosphate-ribose) polymerase may represent a novel therapeutic approach in chronic heart failure: P. Pacher, et al.; J. Am. Coll. Cardiol. 40, 1006 (2002)
  • Novel phenanthridinone inhibitors of poly (adenosine 5'-diphosphate-ribose) synthetase: potent cytoprotective and antishock agents: P. Jagtap, et al.; Crit. Care Med. 30, 1071 (2002)
  • Myocardial protection by PJ34, a novel potent poly (ADP-ribose) synthetase inhibitor: R. Faro, et al.; Ann. Thorac. Surg. 73, 575 (2002)
  • PJ34, an inhibitor of PARP-1, suppresses cell growth and enhances the suppressive effects of cisplatin in liver cancer cells: Oncol. Rep. 20, 567 (2008)
  • The role of PARP activation in glutamate-induced necroptosis in HT-22 cells: X. Xu, et al.; Brain Res. 1343, 206 (2010)
  • Renal hypoperfusion and impaired endothelium-dependent vasodilation in an animal model of VILI: the role of the peroxynitrite-PARP pathway: R. Vaschetto, et al.; Crit. Care 14, R45 (2010)